

Product datasheet for TL309475V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

gamma Sarcoglycan (SGCG) Human shRNA Lentiviral Particle (Locus ID 6445)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: gamma Sarcoglycan (SGCG) Human shRNA Lentiviral Particle (Locus ID 6445)

Locus ID: 6445

Synonyms: 35DAG; A4; DAGA4; DMDA; DMDA1; gamma-SG; LGMD2C; LGMDR5; MAM; SCARMD2; SCG3

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: SGCG - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000231, NM 000231.1, NM 000231.2, BC109321, BC074777, BC074778

UniProt ID: Q13326

Summary: This gene encodes gamma-sarcoglycan, one of several sarcolemmal transmembrane

glycoproteins that interact with dystrophin. The dystrophin-glycoprotein complex (DGC) spans the sarcolemma and is comprised of dystrophin, syntrophin, alpha- and beta-dystroglycans

and sarcoglycans. The DGC provides a structural link between the subsarcolemmal

cytoskeleton and the extracellular matrix of muscle cells. Defects in the encoded protein can

lead to early onset autosomal recessive muscular dystrophy, in particular limb-girdle

muscular dystrophy, type 2C (LGMD2C). [provided by RefSeq, Oct 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).